Kornimate/medical-research-clean huggingface dataset:
effectiveness of a combined group-individual schema therapy for borderline personality disorder

Conditions: Borderline Personality Disorder; Randomized Controlled Trial

Summary: background and objectives: schema therapy has been shown to be of benefit in treating borderline personality disorder. however, it is still unclear what the most suitable treatment implementation format is and to what extent therapeutic gains may be generalizable to regular healthcare settings with limited resources. methods: a pragmatic randomized controlled trial was conducted ona representative spanish sample of outpatients with a dsm-5 main diagnosis of borderline personality disorder. patients were allocated either to a combined (group plus individual) schema therapy format (n=40) or to a group-only schema therapy format (n=40). borderline personality disorder severity was the primary outcome, with other clinical variables considered as secondary outcomes (e.g., early maladaptive schemas, functioning). the assessment protocol included baseline, post-treatment (after 12months of treatment), and six-month follow-up evaluations. data was analyzed through a two-way repeated measures anova. limitations were a limited follow-up assessment and the absence of multi-center data that detracted from the long-term stability and generalizability of the findings.


Eligibility criteria:
inclusion criteria: * dsm-5 criteria for borderline personality disorder * aged 18 to 65 years exclusion criteria: * psychotic disorders (except short, reactive psychotic episodes) * bipolar disorder (current hypo-manic or mixed episode) * antisocial personality disorder * substance intoxication * mental retardation
helping children with trauma

Conditions: Trauma; Post-Traumatic Stress Disorder

Summary: the purpose of this study is to evaluate if a trauma treatment called trauma systems therapy (tst) decreases children's mental health symptoms (such as acting out, not controlling their emotions, etc.) as a result of a traumatic event (or events). a traumatic event or events can include experiencing or witnessing violence, excessive bullying, war, car accident, serious injury, getting mistreated or anything else that makes one feel scared or frightened. children/teens who experience traumatic events have been shown to be at higher risk of poor mental and physical health. trauma can impact family life, school life and interpersonal relationships well into adulthood. unfortunately, most children who have experienced traumatic events do not undergo treatment. although promising treatments do exist, most do not address the complexity of trauma, particularly related to ongoing stress and threats to safety in their environments. one hundred and twenty eligible youth will be randomized to receive either treatment with tst at nyu's child study center or trauma treatment as usual (tau) at a community mental health clinic. it is hypothesized that: * youth receiving tst will demonstrate a greater decrease in post-traumatic stress disorder (ptsd) symptoms at the 3, 6, and 9-month follow-up assessments compared to youth receiving treatment as usual (tau) in the community. * youth receiving tst will demonstrate a greater decrease in symptoms of depression, anxiety and problem behaviors (aggression, violence, self-destructive behaviors, etc.) at the 3-, 6- and 9-month follow-up assessments compared to youth receiving tau. * youth receiving tst will have fewer acute mental health service events, such as psychiatric hospitalizations and ed visits compared to youth receiving tau. * greater fidelity to the tst model is associated with better treatment outcomes among youth receiving tst.


Eligibility criteria:
inclusion criteria: * between the ages of 7 and 17. * have experienced a trauma and have symptoms of that trauma for more than 1 month * have a legal guardian who is willing to give consent and a primary caregiver who will be available for assessments. exclusion criteria: * reside outside the study area * currently participating in another study * do not speak english * receive psychotherapy elsewhere * have a sibling already participating in the study * are acutely suicidal or homicidal * demonstrate they are in immediate danger * legal guardian does not give consent * if the primary caregiver does not speak english, does not have consistent access to a telephone, does not have the capacity to answer questions, the child will be excluded. * if a potential subject has started, stopped, or changed a psychotropic medication within 2 weeks of their intake appointment. if the family is willing to wait for 2 weeks the participant may then be eligible.

Keywords: therapy trauma systems therapy
evaluation of vaccinal and natural immunity against meningococcus c

Conditions: Prevention of Meningococcus C Infections

Summary: meningococcus c vaccine was first used in france to prevent epidemics. it was a success in puy-de-dôme, landes, pyrénées atlantiques and hautes pyrénées. following many european countries, france introduced meningococcus c conjugate vaccine in 2009 but this recommendation was not suffiicently applied (6,6% of the 20-25 years-old were vaccinated in 2015). the situation in france is very different from uk and there is no data on the subject. the vaccination campaign in 2002 in puy-de-dôme offers much more detachment, possible comparison between vaccinated and unvaccinated people, among which meningococcus circulation could maintain immunity. this is the reason why we have decided to assess in 2016 the vaccinal and natural immunity among puy-de-dôme population.

people were recruited during hospitalisation or consultation of pediatric, occupational medecine, infectiology departments of clermont ferrand hospital or health service of auvergne's university, from march to september 2016. doctors gave informations about the study and collected consents before blood tests were done (two tubes of 4,5ml each). blood tests were daily collected and freezed. then they were analysed at meningococcus national reference center, in paris.

Eligibility criteria:
inclusion criteria: * - people from 13 to 39 years old * who received meningococcus c conjugate vaccine in 2002 in puy-de-dôme (vaccinated group) or not (unvaccinated group) exclusion criteria: * vaccination before or after 2002 containing meningococcus c valence * refusal to participate

Keywords: meningococcus c
optoelectronic pletysmography and diaphragmatic thickness in heart failure patients

Conditions: Heart Failure

Summary: the investigators aimed to evaluate the effects of cardiomegaly associated with inspiratory muscle weakness on tricompartmental distribution of chest wall volumes, on the thickness of the right hemidiaphragm and on the contraction speed of the respiratory muscles. as method of the present research, a pilot cross-sectional study was conducted with fourteen (14) patients with heart failure, functional class ii and iii, clinically stable, with cardiomegaly. two groups were formed: one group with inspiratory muscle weakness (wg) (maximal inspiratory pressure - mip \<70% predicted mip) and a control group without weakness (cg). the pulmonary and respiratory muscle functions were assessed by spirometry and manometer, respectively. before and after maximal exercise test, optoelectronic plethysmography was performed to evaluate the distribution of volumes, the kinematics and the contraction speed of chest wall muscles. the high-resolution ultrasonography was also used before and after the maximum test for obtaining diaphragmatic thickness


Eligibility criteria:
inclusion criteria: * both sexes, 18-60 years; * functional class ii-iii according to the new york heart association; * echocardiography of the last six months showing showing left ventricular ejection fraction (lvef) ≤ 45% measured by teichholz method; * echocardiography the last six months showing cardiac hypertrophy (diameter of left ventricular diastolic (lvdd)\> 54 mm, diameter of systolic left ventricular (lvsd)\> 34mm) 30 measured by teichholz method; * optimized by the medical point of view and * clinical stability exclusion criteria: * unstable angina; myocardial infarction or heart surgery up to three months before the survey; * orthopedic diseases, infectious or chronic metabolic diseases; * the relation between forced expiratory volume in the first second and forced vital capacity (fev1 / fvc) \<70% of predicted characterizing obstructive respiratory disorder and * active smokers.
the effect of different types of exercise on insulin resistance and visceral adipose tissue in community residents.

Conditions: Exercise, Insulin Resistance, Visceral Adipose Tissue

Summary: background: exercise has been proven to effectively reduce incidence of diabetes mellitus and metabolic syndrome. however, there is controversial data from prior studies to inform the type of exercise training recommendations. aim: the aim of this study will determine the differences of different type of exercise in the effects of reducing insulin resistance and visceral adipose tissue for community residents. methods: the four-arm randomized controlled trial will conducted in adults aged 40 to 70 years old in tainan. a total of at least 177 patients will randomly assign to the group of aerobic exercise (ae), aerobic exercise combined with resistance exercise (re), ae combined with medium intensity interval training, and placebo. the participants in exercise group will received 12 weeks, 3 times per week program, including twice a week intervention guided by the intervenors, and once a week exercise guided by the video at home. all the exercise keeps moderate-intensity by monitoring with 64%-75% of the maximum heart rate. insulin resistance status will be checked by homa index at baseline and at exercise intervention after 12 weeks (homa index= insulin μu/ml）× glucose（mmol/l）/22.5). relevance to clinical practice: the research findings will help the clinical health works to know which type of exercise is the best choice in reducing insulin resistance and visceral adipose tissue in community residents, and can be promoted to the general public to reduce the prevalence of metabolic syndrome as well as prevent the root causes of ill health.


Eligibility criteria:
inclusion criteria: * adults aged 40 to 70 years old. * without regular exercise in the past six years. exclusion criteria: * recent unstable condition involving stroke or those with heart disease, handicap, pregnancy, mental disorders, systolic bp \> 200 mmhg, or diastolic bp \>110 mmhg. * those with contraindications in body composition analyzer measurement including people with pacemakers, artificial metal joints, amputated hands or feet, and those who cannot be cooperated with standing during testing.
efficacy and safety of apalutamide in combination with 89sr as neoadjuvant therapy in prostate cancer with ≤10 bone metastases

Conditions: Prostate Cancer With ≤10 Bone Metastases

Summary: the aim of this study is to evaluate the efficacy and safety of apalutamide in combination with 89sr as neoadjuvant therapy in prostate cancer with ≤10 bone metastases. the primary endpoint is pfs and the second endpoints are pcr, rpfs, psa response, pain score, number and extent of bone metastases.


Eligibility criteria:
inclusion criteria: 1. prostate cancer confirmed by pathological findings; 2. bone metastasis confirmed by bone scan, the number of bone metastases ≤10 3. agreement to undergo laparoscopic radical prostatectomy + pelvic lymphadenectomy; 4. ecog score of 0 - 1 5. agreement to undergo preoperative and postoperative endocrine therapy and 89sr radionuclide therapy; 6. voluntary signing of an icf for the clinical trial exclusion criteria: 1. any other tumor disease requiring treatment; 2. any organ metastasis confirmed by imaging, such as liver and brain metastases, or the possibility of paralysis due to spinal cord metastasis; 3. a history of epilepsy or any condition that may lead to seizures; 4. severe liver or kidney dysfunction, severe cardiovascular or cerebrovascular diseases, and systemic immune system diseases
heliox in experimental upper airway obstruction

Conditions: Airway Obstruction; Dyspnea

Summary: currently it is common medical wisdom that heliox (mixture of helium in oxygen) with a fraction of helium below 60% is not effective in reducing airway obstruction. the investigators test the hypothesis that heliox with a fraction of helium below 60% is still effective in relieving airway obstruction in a double-blind, randomized and controlled clinical poc study with experimental upper airway obstruction.

heliox is a mixture of helium and oxygen. it is a therapeutic modality that can improve upper and lower airway obstruction. the lower density of helium can help to relieve airway obstruction and is known to lower the work of breathing. the fraction of helium (fhe) in heliox should be maximized (e.g. up to a fraction of 79% with 21% of oxygen added) in order to achieve optimal anti-obstructive outcome and according to the literature a fhe below 60% renders heliox ineffective. objective: we conducted an investigator-initiated trial using different mixtures of helium and oxygen in 44 healthy volunteers in a randomized and double-blinded fashion. methods: after an adjustment phase the subjects were breathing through two different external resistors (intratracheal tube with inner diameter of either 4.0mm or 5.0mm) while gas of different composition (medical air with 79% nitrogen and 21% oxygen as control gas and heliox with a fraction of either 25%, 50% or 75% helium in oxygen, respectively) was provided in a blinded and random fashion. a crossover design was used so that every subject was exposed to every heliox gas mixture. subjects were asked to score their degree of dyspnea after breathing different gas mixtures for 2 minutes intervals. in addition the variability of different hemodynamic parameters was assessed (continuous non-invasive blood pressure (systolic, diastolic and mean blood pressure), impedance cardiography (stroke volume and cardiac output), ecg (heart rate variability)) were assessed non-invasively and used to detected a change in the degree of airway obstruction in respect to the added load and the gas mixture.

Eligibility criteria:
inclusion criteria: * volunteers of both sexes were recruited via posting in student forum of university of witten/herdecke * willingness to spend about 2h in the clinical exp. lab. exclusion criteria: * acute airway infection * history of asthma * smokers * pregnancy * abnormal lab. screen with liver function tests, creat./bun, cbc, blood glucose * anxiety or mood disorder * any chronic disease (incl. lung \& heart disease, cancer, endocrine disorder) * mental retardation

Keywords: airway obstruction heliox different helium content
treatment of iron deficiency anemia with pregnancy

Conditions: Iron Deficiency Anemia of Pregnancy

Summary: iron deficiency anemia is a very common problem accompanying pregnancy. in this study, the investigators are going to compare the efficacy and tolerability of two preparations of oral iron in treatment of iron deficiency anemia with pregnancy.

in this study, the investigators are going to compare two preparations of oral iron in treatment of iron deficiency anemia with pregnancy. a total of 300 pregnant women will be randomly divided into two equal groups (each containing 150 pregnant woman). one group will receive amino acid chelated iron and the other group will receive iron salt (ferrous fumarate). all pregnant women attending the obstetrics outpatient clinic of kasr al aini hospital at 14-18 weeks gestation will be submitted to complete blood picture and serum ferritin. those who prove to have iron deficiency anemia (hemoglobin less than 11g/dl and serum ferritin less than 12ug/l) will be included in the study. all eligible women will be followed up at 22-23, 29-30 and 36-37 weeks' gestation for the change in hemoglobin level and ferritin level. all women will be also enquired about different side effects during treatment period.

Eligibility criteria:
inclusion criteria: * age: 20-40 years * pregnant 14-18 weeks * singleton fetus * hb 7-10.9 g/dl * serum ferritin \<12 microgram/l exclusion criteria: * history of anemia due to other causes as chronic blood loss, hemolytic anemia or thalassemia * multiple pregnancy * known hepatic, renal or cardiovascular abnormality. * known peptic ulcer, esophagitis, gastritis or hiatus hernia. * family history of thalassemia, sickle cell anemia, or malabsorption syndrome. * iron preparation intake within 24 hours of inclusion

Keywords: amino acid chelated iron iron salt iron deficiency anemia
study to analyze the clinical and cost impact of complete and incomplete rotarix vaccination

Conditions: Infections, Rotavirus

Summary: this study aims to estimate the clinical and cost impact of rotarix vaccinations among children aged less than 5 years using insurance claims data from commercial plans and medicaid low-income population. the impact of incomplete and complete rotarix vaccination will also be examined, overall and stratified by calendar time of rotarix vaccination (e.g., 2008 onward).

insurance claims data from the marketscan commercial claims and encounters database {marketscan commercial (2000-2010)} and the marketscan multi-state medicaid database {marketscan medicaid (2002-2009)} will be analyzed separately; no merging of the databases will occur. the claims data extracts are fully de-identified and compliant with the health insurance portability and accountability act of 1996 (u.s.) (hipaa). the children will be observed from birth to the earliest of end of continuous eligibility (due to disenrollment, data cut-off, or death) or 5 years of age. observation time will be classified using two different definitions of rotarix vaccination coverage, and analyses will be conducted for each different scenario. the two definitions for rotarix vaccination coverage are: 1. rotarix vaccination according to compliance with the advisory committee on immunization practices (acip)-specified vaccination window of 6 weeks to 8 months old. 2. rotarix vaccination according to compliance with the rotarix prescribing information (pi) window of 6 weeks to 6 months old. all outcomes will be analysed for 1) vaccination coverage according to compliance with the acip vaccination window, and 2) vaccination coverage according to compliance with pi vaccination window; for both rotarix vaccination coverage scenarios there will be four cohorts. an additional 'complete rotarix vaccination off-acip/off-pi' cohort will be created if more than 5 percent of total person-time in the four cohorts would be complete vaccination if vaccine doses outside of the vaccination window were considered.

Eligibility criteria:
inclusion criteria: * continuously enrolled from birth. (note: due to the absence of birth dates in insurance claims data, this inclusion criterion will be met if a child's year of first enrollment and year of birth are the same. if so, then the date of first enrollment will be used as proxy for date of birth.) * received both medical and pharmacy benefits. exclusion criteria: * enrolled in capitation-based health plans. * for marketscan commercial, residence in states with universal vaccination programs that include the rv vaccine or where rv vaccine inclusion cannot be ascertained (i.e., alaska, idaho, massachusetts, maine, north dakota, new hampshire, new mexico, oregon, rhode island, vermont, washington, wisconsin, and wyoming). * received any rotateq vaccination. * lost to follow-up prior to end of vaccination window or had rv prior to end of vaccination window.

Keywords: clinical children rotavirus cost rotarix vaccination
the role of artery-preserving varicocelectomy in subfertile men with severe oligozoospermia.

Conditions: Infertility, Male; Oligozoospermia; Varicocelectomy

Summary: a male factor is responsible for almost half the cases of subfertility. varicocele is a major cause of impaired spermatogenesis and potentially a correctable cause. it affects up to 40% of men with primary subfertility and 80% of men with secondary subfertility. varicocelectomy is now accepted as a cost effective treatment in subfertile men with clinically palpable varicocele and impaired semen parameters. recently, varicocelectomy is reported to improve fertility potential in patients with severe oligozoospermia. in one such study, varicocelectomy was associated with a statistically significant increase in sperm density and motility. spontaneous pregnancy was achieved in16.7% of cases. in a recent meta-analysis, varicocelectomy in men with severe oligozoospermia showed a strong trend toward improvement in pregnancy rate (pr) \[or= 1.69, 95% ci (0.951, 3.020), p= 0.073\] and statistically significant increase in live birth rate (lbr)\[or=1.699, 95%ci (1.020, 2.831), p= 0.04\]. the impact of ligation of internal spermatic artery (isa) during varicocelectomy is a matter of debate. conventional view is arterial ligation can negatively affect testicular function and decrease the likelihood of post-operative paternity. other investigators reported that ligation of isa was not associated with significant changes in postoperative semen parameters, testicular size or pr in comparison to artery preservation. moreover, laparoscopic artery-ligating varicocelectomy was proved to be superior in the form of shorter operative time and lower recurrence rates with no difference in semen parameters or pr in comparison to laparoscopic artery-preservation varicocelectomy. also, isolation of isa is not an easy task during subinguinal varicocelectomy due to compression by external oblique aponeurosis and its inherent anatomical variation. in 29 % and 57% of the cases, the isa is surrounded by the varicose vessels and adherent to the veins respectively. thus, the isa is liable to a substantial risk of accidental ligation during subinguinal varicocelectomy. whether or not ligation of the isa has a deleterious effect on the fertility outcomes in patients with severe oligozoospermia; this is not clear in the literature. this prospective randomized study was conducted to assess the impact of isa ligation during subinguinal varicocelectomy on fertility outcome in patients with severe oligozoospermia.


Eligibility criteria:
inclusion criteria: * adult sub-fertile male * with clinical varicocele (grade 2,3) severe oligozoospermia (\<5 million/ml) exclusion criteria: * patients' age \ 5 million/ml, history of previous inguinal surgery, concomitant female factor subfertility and refusal to participate in the study.